<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01141478</url>
  </required_header>
  <id_info>
    <org_study_id>5100104</org_study_id>
    <nct_id>NCT01141478</nct_id>
  </id_info>
  <brief_title>Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria</brief_title>
  <official_title>Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared
      to Sorafenib alone will produce the best results for treating patients with Hepatocellular
      Carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>On average followed for 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the radiological progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>On average followed for 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Proton Beam Radiotherapy plus Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiotherapy</intervention_name>
    <description>Fifteen consecutive sessions</description>
    <arm_group_label>Proton Beam Radiotherapy plus Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400 mg po bid</description>
    <arm_group_label>Proton Beam Radiotherapy plus Sorafenib</arm_group_label>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients are candidates to receive both proton beam and sorafenib

          2. Patients with tumor burden that exceeds San Francisco criteria

        Exclusion Criteria:

          1. Patients who are candidates for surgical resection

          2. Patients with tumor burden within Milan and/or San Francisco criteria

          3. Patients who have contraindication to receive proton

          4. Patients with contraindication to receive sorafenib including uncontrolled
             hypertension, coumadin treatment and prior intolerability to the drug

          5. Patients treated previously by any locoregional treatment

          6. Patients with prior liver transplant

          7. Patients with child class C

          8. Patients with model for end-stage liver disease (MELD) score of &gt; 25

          9. Patients with other comorbid diseases that may impact survival

         10. Patients with ongoing alcohol intake

         11. Patients with active sepsis

         12. Patients with gastrointestinal bleeding within a week

         13. Patients unwilling to sign informed consent form

         14. Patients with history of noncompliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael deVera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Scavone</last_name>
    <phone>909-558-3636</phone>
    <email>DScavone@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2010</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Michael Devera, MD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Proton Beam Radiotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 12, 2017</submitted>
    <returned>October 12, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

